INFINITT North America (INA) is excited to share the news of its latest collaboration with Aiforia
Summary
At the same time, fewer medical doctors are specializing in pathology even as sample numbers continue to grow, resulting in a critical imbalance. Dave Smarro, INFINITT CEO, acknowledges that now is the ideal moment for INA to forge alliances with AI firms so they can leverage cutting-edge technology to alleviate staffing shortages while simultaneously enhancing patient care standards. INAs digital pathology solution played a crucial role in achieving the worlds first-ever HIMSS DIAM Stage 7 accreditation for a largely renowned medical campus. Smarro also expressed enthusiasm regarding the prospect of Aiforias Clinical Suites integrating with INAs solutions in diagnosing some of the worlds most common cancers, including prostate, breast, and lung. Working together, INA and Aiforia aim to support overburdened pathologists, update antiquated diagnostic tools, and ultimately diminish waiting periods for the patients who rely on their expertise.
Classifications
AskAI Classifications
LabelsLinked Companies
